BioSpace News Archive

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce the appointment of Graham Phillips as its new Chief Operating Officer, effective immediately.

Pie Medical Imaging which investigates the use of angiography-based vessel fractional flow reserve in patients undergoing coronary revascularization procedures.

Calliditas Therapeutics AB announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) today announces randomization of the first patient in the PRISM-MEL-301 trial, assessing the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02), in combination with nivolumab, in first-line advanced or metastatic cutaneous melanoma.

EyePoint Pharmaceuticals, Inc. today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting in Stockholm, Sweden.

Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC).

Silk Road Medical, Inc. announced it has entered into a definitive agreement to be acquired by Boston Scientific Corporation, a global medical technology leader, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections.

Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.